FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/12/077795 [Registered on: 06/12/2024] Trial Registered Prospectively
Last Modified On: 05/05/2026
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Methylene Blue as an early treatment for septic shock 
Scientific Title of Study   Methylene Blue as an early Adjunctive treatment for septic shock-A Randomized Controlled Trial 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Rishwanth Raja P M 
Designation  Postgraduate 
Affiliation  Sri Ramachandra Institute of Higher Education and Research  
Address  G Block 1st Floor Department of critical care medicine Sri Ramachandra Institute of Higher Education and Research No 1 Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India

Thiruvallur
TAMIL NADU
600116
India 
Phone  8870767379  
Fax    
Email  rishwanthraja123@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Renuka M K 
Designation  Professor 
Affiliation  Sri Ramachandra Institute of Higher Education and Research 
Address  G Block 1st Floor Department of critical care medicine Sri Ramachandra Institute of Higher Education and Research No 1 Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India

Thiruvallur
TAMIL NADU
600116
India 
Phone  8056126336  
Fax    
Email  hod.criticalcare@sriramachandra.edu.in  
 
Details of Contact Person
Public Query
 
Name  Dr Rishwanth Raja P M 
Designation  Postgraduate 
Affiliation  Sri Ramachandra Institute of Higher Education and Research 
Address  G Block 1st Floor Department of critical care medicine Sri Ramachandra Institute of Higher Education and Research No 1 Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India

Thiruvallur
TAMIL NADU
600116
India 
Phone  8870767379  
Fax    
Email  rishwanthraja123@gmail.com  
 
Source of Monetary or Material Support  
Sri Ramachandra Institute of Higher Education and Research No 1 Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India  
 
Primary Sponsor  
Name  DR RISHWANTH RAJA P M 
Address  G Block 1st floor Department of Critical Care Medicine Sri Ramachandra Institute of Higher Education and Research No 1 Ramachandra Nagar Porur Chennai 600116 Tamil Nadu India  
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Rishwanth Raja P M  Sri Ramachandra Institute of Higher Education and Research  G Block 1st floor Room number 09 Department of critical care medicine Sri Ramachandra Institute of Higher Education and Research Number 01 ramachandra nagar Porur Chennai -600116
Thiruvallur
TAMIL NADU 
8870767379

rishwanthraja123@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee Sri Ramachandra Institute of Higher Education and Research Porur Chennai 600116  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: I998||Other disorder of circulatory system,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  METHYLENE BLUE  In septic shock patients, when Norepinephrine dose reached 0.20 mcg/kg/min, Vasopressin is initiated at 0.03IU/min, methylene blue is administered after test dose along with vasopressin, intravenous administration with dosing regimen Bolus of 2mg/kg is given followed by infusion of 0.25mg/kg/h in 0.9% sodium chloride solution for 6 hours given for two consecutive days. Tapering of vasopressors at periodic intervals is followed accordingly. 
Comparator Agent  Vasopressors  The standard protocol of treatment of septic shock is initiated with vasopressors when Norepinephrine dose reached 0.20 mcg/kg/min, Vasopressin is initiated at 0.03IU/min followed by initiation of epinepherine in standard group, Physician-led vasopressor tapering protocol ofnorepinephrine, vasopresssin, epinephrine titration at 15–20min intervals to maintain mean arterial pressure (MAP- 70 mmHg) will be continued. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  1)Age greater than 18 years,
2)Highly suspected or confirmed infection
3)Norepinephrine dose greater than 0.2mcg/kg/min to maintain MAP greater than 65 mmHg
4)Less than 6 hrs of starting noradrenaline
 
 
ExclusionCriteria 
Details  1)Pregnancy
2)Chronic kidney disease
3)Concurrent hemorrhagic, obstructive, cardiogenic, hypovolemic shock,
4)Greater than 24 hours of septic shock,
History of glucose-6-phosphate dehydrogenase deficiency,
5)Allergy to methylene blue
6)Drug interactions: Phenothiazines, selective serotonin re-uptake inhibitors, Dapsone
7)Refusal of the patient or decision maker to participate.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   On-site computer system 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
To assess whether early adjunctive Methylene blue can reduce time to vasopressor discontinuation in patients with septic shock   7 days 14 days 21days 
 
Secondary Outcome  
Outcome  TimePoints 
To assess the effects of continuous infusion of methylene blue on cardiac & renal SOFA scores, serum lactate levels   24 hours 48 hours 72 hours 
 
Target Sample Size   Total Sample Size="120"
Sample Size from India="120" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   11/12/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Patient selection:

Patients aged >18yrs who are highly suspected or confirmed infection, the patients will be checked for volume responsiveness by straight leg rise and capillary refill time after adequate fluid resuscitation with 500ml bolus of balanced crystalloid, if found to have negative response. Patients are initiated on Norepinephrine to maintain MAP>65 mmHg, Patients are selected if time to vasopressor initiation <6hrs. All the components in exclusion criteria will be assessed before eligibility.

 

Randomisation, Intervention, Measurements:

             After informed consent the patients are randomized 1:1  to                                     methylene blue group or the standard group by computer generated simple randomization.

 Both the groups will continue to get similar standard of care according to protocol. When Norepinephrine dose reached >0.20 mcg/kg/min, Vasopressin is initiated at 0.03IU/min in both groups.

In the Methylene blue group, after test dose, the dosing regimen - Bolus of 2mg/kg followed by infusion of 0.25mg/kg/h in 0.9%Nacl solution for 6hrs for two consecutive days.

Physician-led vasopressor tapering protocol of norepinephrine titration at 15–20min intervals to maintain mean arterial pressure (MAP-70 mmHg) will be continued. Our standard protocol calls for the initiation of epinephrine, even after reaching the maximum dose requirement for dual vasopressors. Weaning of vasopressors will also be according to periodic intervals by withdrawal epinephrine followed by vasopressin and norepinephrine. Close monitoring of meth-hemoglobin levels will be done periodically to avoid complications.

Hydrocortisone at 50mg Q6hrly dose is also a standard in our unit,will be initiated and it is withheld after 24-h after discontinuation of all vasopressors.

  
Close